F-Phenibut: Difference between revisions
>Winch F-Phenibut = stronger GABA B agonist, weaker Calcium Channel Blocker. Thus it has a better tolerance profile than Phenibut. F-Phenibut lasts half as long as Phenibut, meaning the difference is not high enough to say that compulsive redosing is more pronounced with the fluorinated version. It's also worth mentioning this characteristic is more specific to dopaminergic and opioidergic agents because of their immediate stimulation of the reward pathway unlike GABAergic and Ion channels depressants. |
>Tracer |
||
(6 intermediate revisions by 5 users not shown) | |||
Line 7: | Line 7: | ||
==Chemistry== | ==Chemistry== | ||
As with [[phenibut]], F-Phenibut is a derivative of [[GABA]], except with a fluorine-substituted phenyl group in the β-position of the molecule. It is a chiral molecule and thus has two potential configurations as (R)- and (S)-enantiomers.<ref>{{cite journal | vauthors=((Dambrova, M.)), ((Zvejniece, L.)), ((Liepinsh, E.)), ((Cirule, H.)), ((Zharkova, O.)), ((Veinberg, G.)), ((Kalvinsh, I.)) | journal=European Journal of Pharmacology | title=Comparative pharmacological activity of optical isomers of phenibut | volume=583 | issue=1 | pages=128–134 | date=31 March 2008 | issn=0014-2999 | doi=10.1016/j.ejphar.2008.01.015}}</ref> It has an almost identical chemical structure to baclofen (only replacing a chlorine with a fluorine atom in the para-position of the phenyl group).<ref>{{cite journal | vauthors=((Shulgina, G. I.)) | journal=The Pavlovian Journal of Biological Science | title=On neurotransmitter mechanisms of reinforcement and internal inhibition | volume=21 | issue=4 | pages=129–140 | date= December 1986 | issn=0093-2213 | doi=10.1007/BF02734511}}</ref> Additionally, the widely prescribed gabapentinoid [[pregabalin]] also possesses a similar structure as phenibut, except that the phenyl group is instead replaced with an isobutyl group in the S configuration. | As with [[phenibut]], F-Phenibut is a derivative of [[GABA]], except with a fluorine-substituted phenyl group in the β-position of the molecule. It is a chiral molecule and thus has two potential configurations as (R)- and (S)-enantiomers.<ref>{{cite journal | vauthors=((Dambrova, M.)), ((Zvejniece, L.)), ((Liepinsh, E.)), ((Cirule, H.)), ((Zharkova, O.)), ((Veinberg, G.)), ((Kalvinsh, I.)) | journal=European Journal of Pharmacology | title=Comparative pharmacological activity of optical isomers of phenibut | volume=583 | issue=1 | pages=128–134 | date=31 March 2008 | issn=0014-2999 | doi=10.1016/j.ejphar.2008.01.015}}</ref> It has an almost identical chemical structure to baclofen (only replacing a chlorine with a fluorine atom in the para-position of the phenyl group).<ref>{{cite journal | vauthors=((Shulgina, G. I.)) | journal=The Pavlovian Journal of Biological Science | title=On neurotransmitter mechanisms of reinforcement and internal inhibition | volume=21 | issue=4 | pages=129–140 | date= December 1986 | issn=0093-2213 | doi=10.1007/BF02734511}}</ref> Additionally, the widely prescribed gabapentinoid [[pregabalin]] also possesses a similar structure as phenibut, except that the phenyl group is instead replaced with an isobutyl group in the S configuration. F-Phenibut is water soluble. | ||
==Pharmacology== | ==Pharmacology== | ||
Line 31: | Line 31: | ||
*'''[[Effect::Dehydration]]''' - Dehydration is typically reported to occur from regular multiday usage or excessive doses; however, it can also be present even in average doses of the substance (although perhaps to a lesser degree than phenibut). | *'''[[Effect::Dehydration]]''' - Dehydration is typically reported to occur from regular multiday usage or excessive doses; however, it can also be present even in average doses of the substance (although perhaps to a lesser degree than phenibut). | ||
*'''[[Effect::Temperature regulation loss]]''' | *'''[[Effect::Temperature regulation loss]]''' | ||
*'''[[Effect::Headaches]]''' - Moderate to high doses have been reported to | *'''[[Effect::Headaches]]''' - Moderate to high doses have been reported to induce a mild to strong headache, typically many hours after dosing or during the comedown period. | ||
*'''[[Effect::Muscle cramps]]''' - Muscle cramps and joint pain are sometimes accompanied at high doses. | *'''[[Effect::Muscle cramps]]''' - Muscle cramps and joint pain are sometimes accompanied at high doses. | ||
*'''[[Effect::Frequent urination]]''' | *'''[[Effect::Frequent urination]]''' | ||
Line 40: | Line 40: | ||
|{{effects/cognitive| | |{{effects/cognitive| | ||
*'''[[Effect::Empathy, love, and sociability enhancement]]''' - Unlike [[alcohol]] which merely increases sociability through [[disinhibition]], F-Phenibut presents entactogenic effects which, although much weaker than that of traditional [[entactogens]] such as [[MDMA]], are still prominent and well-defined even at moderate doses. | *'''[[Effect::Empathy, love, and sociability enhancement]]''' - Unlike [[alcohol]] which merely increases sociability through [[disinhibition]], F-Phenibut presents entactogenic effects which, although much weaker than that of traditional [[entactogens]] such as [[MDMA]], are still prominent and well-defined even at moderate doses. | ||
*'''[[Effect::Compulsive redosing]]''' - This component is highly pronounced in comparison to [[phenibut]]. | |||
*'''[[Effect::Disinhibition]]''' | *'''[[Effect::Disinhibition]]''' | ||
*'''[[Effect::Analysis suppression]]''' - High doses will usually induce a state of mild stupor and confusion. | *'''[[Effect::Analysis suppression]]''' - High doses will usually induce a state of mild stupor and confusion. | ||
Line 68: | Line 69: | ||
===Tolerance and addiction potential=== | ===Tolerance and addiction potential=== | ||
F-Phenibut is [[Addiction potential::moderately physically and psychologically addictive]], although this usually only occurs with heavy abuse of the substance. | F-Phenibut is [[Addiction potential::moderately physically and psychologically addictive]], although this usually only occurs with heavy abuse of the substance. This is likely even more so than its predecessor [[phenibut]] since its more rapid onset allows more convenient compulsive redosing. | ||
Tolerance will develop to the sedative-hypnotic effects [[Time to full tolerance::within a couple of days of continuous use]]. After cessation, the tolerance returns to baseline in [[Time to zero tolerance::7 - 14 days]]. Withdrawal symptoms or rebound symptoms may occur after ceasing usage abruptly following a few weeks or longer of steady dosing and may necessitate a [[tapering|gradual dose reduction]]. | Tolerance will develop to the sedative-hypnotic effects [[Time to full tolerance::within a couple of days of continuous use]]. After cessation, the tolerance returns to baseline in [[Time to zero tolerance::7 - 14 days]]. Withdrawal symptoms or rebound symptoms may occur after ceasing usage abruptly following a few weeks or longer of steady dosing and may necessitate a [[tapering|gradual dose reduction]]. | ||
Line 105: | Line 106: | ||
<references /> | <references /> | ||
[[Category:Psychoactive substance]] | [[Category:Psychoactive substance]] | ||
[[Category:Gamma-Amino acid]] | |||
[[Category:Phenethylamine]] | |||
[[Category:Depressant]] | [[Category:Depressant]] | ||
[[Category:Anxiolytics]] | [[Category:Anxiolytics]] |